Analysis: Outlook on Medtronic's Endeavor stent

10/18/2007 | Bloomberg Businessweek

Medtronic's Endeavor drug-coated stent, which an FDA advisory panel recommended for approval, will still face safety concerns from regulators, doctors and patients, this analysis says. The company also recognizes it will face marketing concerns, and one executive says, "We expect there will be renewed usage of drug-eluting stents. But we don't think the market will return to its peak."

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
PacificSource
Boise, ID